{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:35:11Z","timestamp":1793928911368,"version":"4.8.0"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03060-x","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T03:01:23Z","timestamp":1755918083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Research progress of mRNA vaccines for infectious diseases"],"prefix":"10.1186","volume":"30","author":[{"given":"Zhen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"issue":"12","key":"3060_CR1","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1128\/CVI.00290-09","volume":"16","author":"SA Plotkin","year":"2009","unstructured":"Plotkin SA. Vaccines: the fourth century. Clin Vaccine Immunol. 2009;16(12):1709\u201319.","journal-title":"Clin Vaccine Immunol"},{"key":"3060_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032700","author":"V Gote","year":"2023","unstructured":"Gote V, et al. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24032700.","journal-title":"Int J Mol Sci"},{"key":"3060_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.903424","volume":"10","author":"P Shan","year":"2022","unstructured":"Shan P, et al. A new nano adjuvant of PF3 used for an enhanced hepatitis B vaccine. Front Bioeng Biotechnol. 2022;10: 903424.","journal-title":"Front Bioeng Biotechnol"},{"key":"3060_CR4","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/190576a0","volume":"190","author":"S Brenner","year":"1961","unstructured":"Brenner S, Jacob F, Meselson M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature. 1961;190:576\u201381.","journal-title":"Nature"},{"issue":"10","key":"3060_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Karik\u00f3 K, T\u00fcreci \u00d6. mRNA-based therapeutics\u2013developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759\u201380.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3060_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5501\/wjv.v12.i5.242","volume":"12","author":"P Mohanty","year":"2023","unstructured":"Mohanty P, et al. Emerging perspectives on RNA virus-mediated infections: from pathogenesis to therapeutic interventions. World J Virol. 2023;12(5):242\u201355.","journal-title":"World J Virol"},{"key":"3060_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122682","author":"L Yang","year":"2022","unstructured":"Yang L, et al. Recent advances in lipid nanoparticles for delivery of mRNA. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14122682.","journal-title":"Pharmaceutics"},{"issue":"11","key":"3060_CR8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","volume":"23","author":"N Pardi","year":"2024","unstructured":"Pardi N, Krammer F. mRNA vaccines for infectious diseases - advances, challenges and opportunities. Nat Rev Drug Discov. 2024;23(11):838\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"3060_CR9","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.74299.1","volume":"10","author":"T Kubota","year":"2021","unstructured":"Kubota T, et al. Case report: isolated, unilateral oculomotor palsy with anti-GQ1b antibody following COVID-19 vaccination. F1000Res. 2021;10: 1142.","journal-title":"F1000Res"},{"issue":"1","key":"3060_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","volume":"8","author":"G Zhang","year":"2023","unstructured":"Zhang G, et al. mRNA vaccines in disease prevention and treatment. Signal Transduct Target Ther. 2023;8(1):365.","journal-title":"Signal Transduct Target Ther"},{"key":"3060_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev-bioeng-110220-031722","volume":"24","author":"J Chen","year":"2022","unstructured":"Chen J, Chen J, Xu Q. Current developments and challenges of mRNA vaccines. Annu Rev Biomed Eng. 2022;24:85\u2013109.","journal-title":"Annu Rev Biomed Eng"},{"key":"3060_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040586","author":"E Whitlow","year":"2020","unstructured":"Whitlow E, Mustafa AS, Hanif SNM. An overview of the development of new vaccines for tuberculosis. Vaccines (Basel). 2020. https:\/\/doi.org\/10.3390\/vaccines8040586.","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"3060_CR13","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1473-3099(19)30625-5","volume":"20","author":"LK Schrager","year":"2020","unstructured":"Schrager LK, et al. The status of tuberculosis vaccine development. Lancet Infect Dis. 2020;20(3):e28\u201337.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"3060_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40005-022-00569-9","volume":"52","author":"P Karmacharya","year":"2022","unstructured":"Karmacharya P, Patil BR, Kim JO. Recent advancements in lipid-mRNA nanoparticles as a treatment option for cancer immunotherapy. J Pharm Investig. 2022;52(4):415\u201326.","journal-title":"J Pharm Investig"},{"issue":"3","key":"3060_CR15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ejpb.2008.09.016","volume":"71","author":"A Yamamoto","year":"2009","unstructured":"Yamamoto A, et al. Current prospects for mRNA gene delivery. Eur J Pharm Biopharm. 2009;71(3):484\u20139.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"3060_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1586\/14760584.2015.973859","volume":"14","author":"D Weissman","year":"2015","unstructured":"Weissman D. mRNA transcript therapy. Expert Rev Vaccines. 2015;14(2):265\u201381.","journal-title":"Expert Rev Vaccines"},{"issue":"11","key":"3060_CR17","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/17460441.2021.1935859","volume":"16","author":"KKW To","year":"2021","unstructured":"To KKW, Cho WCS. An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opin Drug Discov. 2021;16(11):1307\u201317.","journal-title":"Expert Opin Drug Discov"},{"issue":"16","key":"3060_CR18","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1093\/nar\/gkw551","volume":"44","author":"A Ramanathan","year":"2016","unstructured":"Ramanathan A, Robb GB, Chan SH. mRNA capping: biological functions and applications. Nucleic Acids Res. 2016;44(16):7511\u201326.","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"3060_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz751","volume":"47","author":"J Wang","year":"2019","unstructured":"Wang J, et al. Quantifying the RNA cap epitranscriptome reveals novel caps in cellular and viral RNA. Nucleic Acids Res. 2019;47(20): e130.","journal-title":"Nucleic Acids Res"},{"issue":"7830","key":"3060_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett KS, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567\u201371.","journal-title":"Nature"},{"key":"3060_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.biomaterials.2017.11.034","volume":"156","author":"H Kwon","year":"2018","unstructured":"Kwon H, et al. Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine. Biomaterials. 2018;156:172\u201393.","journal-title":"Biomaterials"},{"issue":"7947","key":"3060_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41586-022-05668-z","volume":"614","author":"V Despic","year":"2023","unstructured":"Despic V, Jaffrey SR. mRNA ageing shapes the Cap2 methylome in mammalian mRNA. Nature. 2023;614(7947):358\u201366.","journal-title":"Nature"},{"key":"3060_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","volume":"65","author":"N Pardi","year":"2020","unstructured":"Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol. 2020;65:14\u201320.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"3060_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.39","volume":"1","author":"JM Henderson","year":"2021","unstructured":"Henderson JM, et al. Cap 1 messenger RNA synthesis with co-transcriptional cleancap(\u00ae) analog by in vitro transcription. Curr Protoc. 2021;1(2): e39.","journal-title":"Curr Protoc"},{"issue":"7844","key":"3060_CR25","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1038\/s41586-020-03102-w","volume":"590","author":"U Sahin","year":"2021","unstructured":"Sahin U, et al. Publisher correction: COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature. 2021;590(7844):E17.","journal-title":"Nature"},{"key":"3060_CR26","unstructured":"\u80e1\u52c7, et al., \u4e00\u79cdCap2\u7ed3\u67845\u2032\u5e3d\u5b50\u7c7b\u4f3c\u7269\u53ca\u5176\u5236\u5907\u65b9\u6cd5\u548c\u5e94\u7528. p. 15."},{"issue":"18","key":"3060_CR27","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1007\/s00018-004-4255-0","volume":"61","author":"JP Carralot","year":"2004","unstructured":"Carralot JP, et al. Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Mol Life Sci. 2004;61(18):2418\u201324.","journal-title":"Cell Mol Life Sci"},{"key":"3060_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2020.107534","volume":"40","author":"Y Weng","year":"2020","unstructured":"Weng Y, et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv. 2020;40: 107534.","journal-title":"Biotechnol Adv"},{"issue":"1","key":"3060_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/synbio\/ysaa006","volume":"5","author":"S Balzer Le","year":"2020","unstructured":"Balzer Le S, et al. Dual UTR-a novel 5\u2019 untranslated region design for synthetic biology applications. Synth Biol (Oxf). 2020;5(1): ysaa006.","journal-title":"Synth Biol (Oxf)"},{"issue":"3","key":"3060_CR30","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nrm.2017.103","volume":"19","author":"K Leppek","year":"2018","unstructured":"Leppek K, Das R, Barna M. Functional 5\u2019 UTR mRNA structures in eukaryotic translation regulation and how to find them. Nat Rev Mol Cell Biol. 2018;19(3):158\u201374.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"3060_CR31","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/mt.2012.7","volume":"20","author":"K Karik\u00f3","year":"2012","unstructured":"Karik\u00f3 K, et al. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther. 2012;20(5):948\u201353.","journal-title":"Mol Ther"},{"issue":"11","key":"3060_CR32","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.3727\/096368912X653165","volume":"21","author":"A Sepac","year":"2012","unstructured":"Sepac A, et al. Comparison of cardiomyogenic potential among human ESC and iPSC lines. Cell Transplant. 2012;21(11):2523\u201330.","journal-title":"Cell Transplant"},{"key":"3060_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-genet-120116-024704","volume":"51","author":"C Mayr","year":"2017","unstructured":"Mayr C. Regulation by 3\u2019-untranslated regions. Annu Rev Genet. 2017;51:171\u201394.","journal-title":"Annu Rev Genet"},{"issue":"5","key":"3060_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4161\/rna.20231","volume":"9","author":"E Matoulkova","year":"2012","unstructured":"Matoulkova E, et al. The role of the 3\u2019 untranslated region in post-transcriptional regulation of protein expression in mammalian cells. RNA Biol. 2012;9(5):563\u201376.","journal-title":"RNA Biol"},{"issue":"3","key":"3060_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/0092-8674(85)90200-4","volume":"40","author":"J Pelletier","year":"1985","unstructured":"Pelletier J, Sonenberg N. Insertion mutagenesis to increase secondary structure within the 5\u2019 noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell. 1985;40(3):515\u201326.","journal-title":"Cell"},{"key":"3060_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.gene.2019.05.008","volume":"707","author":"F Zarghampoor","year":"2019","unstructured":"Zarghampoor F, et al. Improved translation efficiency of therapeutic mRNA. Gene. 2019;707:231\u20138.","journal-title":"Gene"},{"key":"3060_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034728","author":"C Mayr","year":"2019","unstructured":"Mayr C. What are 3\u2019 UTRs doing? Cold Spring Harb Perspect Biol. 2019. https:\/\/doi.org\/10.1101\/cshperspect.a034728.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"3060_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","volume":"34","author":"M Fotin-Mleczek","year":"2011","unstructured":"Fotin-Mleczek M, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. 2011;34(1):1\u201315.","journal-title":"J Immunother"},{"issue":"1","key":"3060_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pharmthera.2007.01.002","volume":"114","author":"W Eberhardt","year":"2007","unstructured":"Eberhardt W, et al. Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther. 2007;114(1):56\u201373.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3060_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/1751-7915.13974","volume":"15","author":"H Br\u00fcssow","year":"2022","unstructured":"Br\u00fcssow H. mRNA vaccines against COVID-19: a showcase for the importance of microbial biotechnology. Microb Biotechnol. 2022;15(1):135\u201348.","journal-title":"Microb Biotechnol"},{"issue":"11","key":"3060_CR41","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4161\/rna.22269","volume":"9","author":"T Schlake","year":"2012","unstructured":"Schlake T, et al. Developing mRNA-vaccine technologies. RNA Biol. 2012;9(11):1319\u201330.","journal-title":"RNA Biol"},{"issue":"11","key":"3060_CR42","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1101\/gad.5.11.2108","volume":"5","author":"DR Gallie","year":"1991","unstructured":"Gallie DR. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev. 1991;5(11):2108\u201316.","journal-title":"Genes Dev"},{"issue":"12","key":"3060_CR43","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/nsmb.3499","volume":"24","author":"SA Lima","year":"2017","unstructured":"Lima SA, et al. Short poly(A) tails are a conserved feature of highly expressed genes. Nat Struct Mol Biol. 2017;24(12):1057\u201363.","journal-title":"Nat Struct Mol Biol"},{"issue":"13","key":"3060_CR44","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","volume":"108","author":"S Holtkamp","year":"2006","unstructured":"Holtkamp S, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009\u201317.","journal-title":"Blood"},{"key":"3060_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1101\/sqb.2019.84.039818","volume":"84","author":"TTL Tang","year":"2019","unstructured":"Tang TTL, Passmore LA. Recognition of poly(A) RNA through its intrinsic helical structure. Cold Spring Harb Symp Quant Biol. 2019;84:21\u201330.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"9","key":"3060_CR46","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41580-020-0246-8","volume":"21","author":"S Yu","year":"2020","unstructured":"Yu S, Kim VN. A tale of non-canonical tails: gene regulation by post-transcriptional RNA tailing. Nat Rev Mol Cell Biol. 2020;21(9):542\u201356.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"3060_CR47","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1261\/rna.069286.118","volume":"25","author":"Z Trepotec","year":"2019","unstructured":"Trepotec Z, et al. Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life. RNA. 2019;25(4):507\u201318.","journal-title":"RNA"},{"issue":"11","key":"3060_CR48","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3 K, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833\u201340.","journal-title":"Mol Ther"},{"issue":"16","key":"3060_CR49","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","volume":"39","author":"SS Rosa","year":"2021","unstructured":"Rosa SS, et al. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine. 2021;39(16):2190\u2013200.","journal-title":"Vaccine"},{"key":"3060_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608460","volume":"11","author":"JB Sandbrink","year":"2020","unstructured":"Sandbrink JB, Shattock RJ. RNA vaccines: a suitable platform for tackling emerging pandemics? Front Immunol. 2020;11: 608460.","journal-title":"Front Immunol"},{"key":"3060_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23123310","author":"K Lundstrom","year":"2018","unstructured":"Lundstrom K. Self-replicating RNA viruses for RNA therapeutics. Molecules. 2018. https:\/\/doi.org\/10.3390\/molecules23123310.","journal-title":"Molecules"},{"issue":"2","key":"3060_CR52","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","volume":"26","author":"AB Vogel","year":"2018","unstructured":"Vogel AB, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther. 2018;26(2):446\u201355.","journal-title":"Mol Ther"},{"issue":"36","key":"3060_CR53","doi-asserted-by":"publisher","first-page":"14604","DOI":"10.1073\/pnas.1209367109","volume":"109","author":"AJ Geall","year":"2012","unstructured":"Geall AJ, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012;109(36):14604\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"3060_CR54","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1038\/mt.2014.133","volume":"22","author":"LA Brito","year":"2014","unstructured":"Brito LA, et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther. 2014;22(12):2118\u201329.","journal-title":"Mol Ther"},{"issue":"3\u20134","key":"3060_CR55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","volume":"28","author":"K Bloom","year":"2021","unstructured":"Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2021;28(3\u20134):117\u201329.","journal-title":"Gene Ther"},{"issue":"2","key":"3060_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020097","volume":"9","author":"AK Blakney","year":"2021","unstructured":"Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines. 2021;9(2): 97.","journal-title":"Vaccines"},{"key":"3060_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101262","volume":"44","author":"KM Pollock","year":"2022","unstructured":"Pollock KM, et al. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: covac1, a phase I, dose-ranging trial. EClinicalMedicine. 2022;44: 101262.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"3060_CR58","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1473-3099(23)00650-3","volume":"24","author":"Y Oda","year":"2024","unstructured":"Oda Y, et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infect Dis. 2024;24(4):351\u201360.","journal-title":"Lancet Infect Dis"},{"key":"3060_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12030318","author":"N Silva-Pilipich","year":"2024","unstructured":"Silva-Pilipich N, et al. Self-amplifying RNA: a second revolution of mRNA vaccines against COVID-19. Vaccines. 2024. https:\/\/doi.org\/10.3390\/vaccines12030318.","journal-title":"Vaccines"},{"key":"3060_CR60","doi-asserted-by":"crossref","unstructured":"Komori M, et al. Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine. bioRxiv, 2023.","DOI":"10.1101\/2023.11.01.565056"},{"issue":"5","key":"3060_CR61","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41587-024-02306-z","volume":"43","author":"JE McGee","year":"2025","unstructured":"McGee JE, et al. Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency. Nat Biotechnol. 2025;43(5):720\u20136.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"3060_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","volume":"28","author":"T Beissert","year":"2020","unstructured":"Beissert T, et al. A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol Ther. 2020;28(1):119\u201328.","journal-title":"Mol Ther"},{"key":"3060_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101600","author":"AD Perenkov","year":"2023","unstructured":"Perenkov AD, et al. In vitro transcribed RNA-based platform vaccines: past, present, and future. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11101600.","journal-title":"Vaccines"},{"key":"3060_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/cells13232033","author":"X Yin","year":"2024","unstructured":"Yin X, Li H, Zhou Y. Circular RNAs in viral infection and antiviral treatment. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13232033.","journal-title":"Cells"},{"issue":"12","key":"3060_CR65","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.7150\/ijbs.22531","volume":"13","author":"M Wang","year":"2017","unstructured":"Wang M, et al. Circular RNAs: a novel type of non-coding RNA and their potential implications in antiviral immunity. Int J Biol Sci. 2017;13(12):1497\u2013506.","journal-title":"Int J Biol Sci"},{"issue":"12","key":"3060_CR66","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1080\/15476286.2017.1367886","volume":"14","author":"L Liu","year":"2017","unstructured":"Liu L, et al. Circular RNAs: isolation, characterization and their potential role in diseases. RNA Biol. 2017;14(12):1715\u201321.","journal-title":"RNA Biol"},{"issue":"16","key":"3060_CR67","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1111\/jcmm.17473","volume":"26","author":"R Liu","year":"2022","unstructured":"Liu R, et al. CircRNA: regulatory factors and potential therapeutic targets in inflammatory dermatoses. J Cell Mol Med. 2022;26(16):4389\u2013400.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"3060_CR68","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","volume":"27","author":"G Maruggi","year":"2019","unstructured":"Maruggi G, et al. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther. 2019;27(4):757\u201372.","journal-title":"Mol Ther"},{"issue":"12","key":"3060_CR69","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394.","journal-title":"Nat Rev Mater"},{"issue":"4","key":"3060_CR70","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1021\/acsnano.8b07858","volume":"13","author":"J Buck","year":"2019","unstructured":"Buck J, et al. Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery. ACS Nano. 2019;13(4):3754\u201382.","journal-title":"ACS Nano"},{"key":"3060_CR71","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","volume":"170","author":"J Kim","year":"2021","unstructured":"Kim J, et al. Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021;170:83\u2013112.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"3060_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201906128","volume":"32","author":"S Ramishetti","year":"2020","unstructured":"Ramishetti S, et al. A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes. Adv Mater. 2020;32(12): e1906128.","journal-title":"Adv Mater"},{"key":"3060_CR73","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","volume":"154\u2013155","author":"E Samaridou","year":"2020","unstructured":"Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: current perspectives. Adv Drug Deliv Rev. 2020;154\u2013155:37\u201363.","journal-title":"Adv Drug Deliv Rev"},{"key":"3060_CR74","doi-asserted-by":"crossref","unstructured":"Omo-Lamai S, et al. Lipid nanoparticle-associated inflammation is triggered by sensing of endosomal damage: engineering endosomal escape without side effects. bioRxiv, 2024.","DOI":"10.1101\/2024.04.16.589801"},{"issue":"11","key":"3060_CR75","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/s41551-024-01256-w","volume":"8","author":"N Chaudhary","year":"2024","unstructured":"Chaudhary N, et al. Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d. Nat Biomed Eng. 2024;8(11):1483\u201398.","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"3060_CR76","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple SC, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172\u20136.","journal-title":"Nat Biotechnol"},{"issue":"34","key":"3060_CR77","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman M, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012;51(34):8529\u201333.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"5","key":"3060_CR78","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nbt1402","volume":"26","author":"A Akinc","year":"2008","unstructured":"Akinc A, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008;26(5):561\u20139.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"3060_CR79","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1073\/pnas.1322937111","volume":"111","author":"Y Dong","year":"2014","unstructured":"Dong Y, et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci U S A. 2014;111(11):3955\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"3060_CR80","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier MA, et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther. 2013;21(8):1570\u20138.","journal-title":"Mol Ther"},{"key":"3060_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5277","volume":"5","author":"KA Whitehead","year":"2014","unstructured":"Whitehead KA, et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun. 2014;5: 4277.","journal-title":"Nat Commun"},{"key":"3060_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201606944","author":"OS Fenton","year":"2017","unstructured":"Fenton OS, et al. Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes. Adv Mater. 2017. https:\/\/doi.org\/10.1002\/adma.201606944.","journal-title":"Adv Mater"},{"issue":"15","key":"3060_CR83","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1002\/adma.201505822","volume":"28","author":"OS Fenton","year":"2016","unstructured":"Fenton OS, et al. Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery. Adv Mater. 2016;28(15):2939\u201343.","journal-title":"Adv Mater"},{"issue":"3","key":"3060_CR84","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","volume":"110","author":"DJA Crommelin","year":"2021","unstructured":"Crommelin DJA, et al. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. 2021;110(3):997\u20131001.","journal-title":"J Pharm Sci"},{"key":"3060_CR85","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc2315","author":"X Zhang","year":"2020","unstructured":"Zhang X, et al. Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Sci Adv. 2020. https:\/\/doi.org\/10.1126\/sciadv.abc2315.","journal-title":"Sci Adv"},{"issue":"12","key":"3060_CR86","doi-asserted-by":"publisher","first-page":"8099","DOI":"10.1021\/acs.nanolett.5b03528","volume":"15","author":"B Li","year":"2015","unstructured":"Li B, et al. An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo. Nano Lett. 2015;15(12):8099\u2013107.","journal-title":"Nano Lett"},{"issue":"1","key":"3060_CR87","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41565-019-0600-1","volume":"15","author":"X Hou","year":"2020","unstructured":"Hou X, et al. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat Nanotechnol. 2020;15(1):41\u20136.","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"3060_CR88","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ymthe.2019.03.003","volume":"27","author":"A Conway","year":"2019","unstructured":"Conway A, et al. Non-viral delivery of Zinc Finger Nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets. Mol Ther. 2019;27(4):866\u201377.","journal-title":"Mol Ther"},{"issue":"6","key":"3060_CR89","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis S, et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol Ther. 2018;26(6):1509\u201319.","journal-title":"Mol Ther"},{"issue":"10","key":"3060_CR90","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","volume":"37","author":"L Miao","year":"2019","unstructured":"Miao L, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019;37(10):1174\u201385.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"3060_CR91","doi-asserted-by":"publisher","first-page":"E1941","DOI":"10.1073\/pnas.1619653114","volume":"114","author":"S Ramaswamy","year":"2017","unstructured":"Ramaswamy S, et al. Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci U S A. 2017;114(10):E1941-e1950.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"3060_CR92","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn JD, et al. A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 2018;22(9):2227\u201335.","journal-title":"Cell Rep"},{"issue":"7","key":"3060_CR93","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1021\/acs.molpharmaceut.2c00033","volume":"19","author":"F Ferraresso","year":"2022","unstructured":"Ferraresso F, et al. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells. Mol Pharm. 2022;19(7):2175\u201382.","journal-title":"Mol Pharm"},{"issue":"6","key":"3060_CR94","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"JM Richner","year":"2017","unstructured":"Richner JM, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168(6):1114-1125.e10.","journal-title":"Cell"},{"key":"3060_CR95","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","volume":"235","author":"S Chen","year":"2016","unstructured":"Chen S, et al. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J Control Release. 2016;235:236\u201344.","journal-title":"J Control Release"},{"key":"3060_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9010065","author":"MD Buschmann","year":"2021","unstructured":"Buschmann MD, et al. Nanomaterial delivery systems for mRNA vaccines. Vaccines (Basel). 2021. https:\/\/doi.org\/10.3390\/vaccines9010065.","journal-title":"Vaccines (Basel)"},{"key":"3060_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett KJ, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids. 2019;15:1\u201311.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3060_CR98","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.3c14010","author":"K Yang","year":"2024","unstructured":"Yang K, et al. Biodegradable lipid-modified poly(guanidine thioctic acid)s: a fortifier of lipid nanoparticles to promote the efficacy and safety of mRNA cancer vaccines. J Am Chem Soc. 2024. https:\/\/doi.org\/10.1021\/jacs.3c14010.","journal-title":"J Am Chem Soc"},{"key":"3060_CR99","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jconrel.2020.06.027","volume":"325","author":"G Lou","year":"2020","unstructured":"Lou G, et al. Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: the impact of cationic lipid selection. J Control Release. 2020;325:370\u20139.","journal-title":"J Control Release"},{"key":"3060_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12070607","author":"B Tang","year":"2020","unstructured":"Tang B, Qian Y, Fang G. Development of lipid-polymer hybrid nanoparticles for improving oral absorption of Enoxaparin. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12070607.","journal-title":"Pharmaceutics"},{"issue":"4","key":"3060_CR101","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"3060_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/nano10020364","author":"I G\u00f3mez-Aguado","year":"2020","unstructured":"G\u00f3mez-Aguado I, et al. Nanomedicines to deliver mRNA: state of the art and future perspectives. Nanomaterials. 2020. https:\/\/doi.org\/10.3390\/nano10020364.","journal-title":"Nanomaterials"},{"issue":"1","key":"3060_CR103","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1038\/s41467-024-50619-z","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu Y, et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat Commun. 2024;15(1):6305.","journal-title":"Nat Commun"},{"key":"3060_CR104","doi-asserted-by":"crossref","unstructured":"Witten J, et al. Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. Nat Biotechnol. 2024.","DOI":"10.1038\/s41587-024-02490-y"},{"issue":"3","key":"3060_CR105","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41587-023-01774-z","volume":"42","author":"A Vander Straeten","year":"2024","unstructured":"Vander Straeten A, et al. A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. Nat Biotechnol. 2024;42(3):510\u20137.","journal-title":"Nat Biotechnol"},{"key":"3060_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28073132","author":"Y Meng","year":"2023","unstructured":"Meng Y, et al. Cell-free expression of a therapeutic protein Serratiopeptidase. Molecules. 2023. https:\/\/doi.org\/10.3390\/molecules28073132.","journal-title":"Molecules"},{"issue":"1","key":"3060_CR107","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41541-025-01093-1","volume":"10","author":"R Munoz-Moreno","year":"2025","unstructured":"Munoz-Moreno R, et al. A highly stable lyophilized mRNA vaccine for Herpes zoster provides potent cellular and humoral responses. NPJ Vaccines. 2025;10(1):49.","journal-title":"NPJ Vaccines"},{"issue":"1","key":"3060_CR108","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41421-022-00517-9","volume":"9","author":"L Ai","year":"2023","unstructured":"Ai L, et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov. 2023;9(1):9.","journal-title":"Cell Discov"},{"issue":"1","key":"3060_CR109","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41541-022-00549-y","volume":"7","author":"EA Voigt","year":"2022","unstructured":"Voigt EA, et al. A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. NPJ Vaccines. 2022;7(1):136.","journal-title":"NPJ Vaccines"},{"key":"3060_CR110","first-page":"71","volume":"440","author":"C Zeng","year":"2022","unstructured":"Zeng C, et al. Formulation and delivery technologies for mRNA vaccines. Curr Top Microbiol Immunol. 2022;440:71\u2013110.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"29","key":"3060_CR111","doi-asserted-by":"publisher","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","volume":"113","author":"JS Chahal","year":"2016","unstructured":"Chahal JS, et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci U S A. 2016;113(29):E4133\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3060_CR112","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1038\/s41598-017-03670-4","volume":"7","author":"W Li","year":"2017","unstructured":"Li W, et al. West Nile virus infectious replicon particles generated using a packaging-restricted cell line is a safe reporter system. Sci Rep. 2017;7(1):3286.","journal-title":"Sci Rep"},{"key":"3060_CR113","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.carbpol.2017.02.036","volume":"168","author":"P Lv","year":"2017","unstructured":"Lv P, et al. Modified-epsilon-polylysine-grafted-PEI-\u03b2-cyclodextrin supramolecular carrier for gene delivery. Carbohydr Polym. 2017;168:103\u201311.","journal-title":"Carbohydr Polym"},{"issue":"6","key":"3060_CR114","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/jbm.a.36033","volume":"105","author":"DR Wilson","year":"2017","unstructured":"Wilson DR, et al. Continuous microfluidic assembly of biodegradable poly(beta-amino ester)\/DNA nanoparticles for enhanced gene delivery. J Biomed Mater Res A. 2017;105(6):1813\u201325.","journal-title":"J Biomed Mater Res A"},{"issue":"7","key":"3060_CR115","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/sj.mt.6300132","volume":"15","author":"GT Zugates","year":"2007","unstructured":"Zugates GT, et al. Rapid optimization of gene delivery by parallel end-modification of poly(\u03b2-amino ester)s. Mol Ther. 2007;15(7):1306\u201312.","journal-title":"Mol Ther"},{"issue":"44","key":"3060_CR116","doi-asserted-by":"publisher","first-page":"13808","DOI":"10.1002\/anie.201608450","volume":"55","author":"JC Kaczmarek","year":"2016","unstructured":"Kaczmarek JC, et al. Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs. Angew Chem Int Ed Engl. 2016;55(44):13808\u201312.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"36","key":"3060_CR117","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201802081","volume":"14","author":"SJ Maassen","year":"2018","unstructured":"Maassen SJ, van der Schoot P, Cornelissen J. Experimental and theoretical determination of the pH inside the confinement of a virus-like particle. Small. 2018;14(36): e1802081.","journal-title":"Small"},{"issue":"4","key":"3060_CR118","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1021\/ja808856z","volume":"131","author":"CS Thaxton","year":"2009","unstructured":"Thaxton CS, et al. Templated spherical high density lipoprotein nanoparticles. J Am Chem Soc. 2009;131(4):1384\u20135.","journal-title":"J Am Chem Soc"},{"key":"3060_CR119","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2019.10.026","volume":"314","author":"Y Qiu","year":"2019","unstructured":"Qiu Y, et al. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. J Control Release. 2019;314:102\u201315.","journal-title":"J Control Release"},{"issue":"1","key":"3060_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#","volume":"30","author":"I Hoerr","year":"2000","unstructured":"Hoerr I, et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000;30(1):1\u20137.","journal-title":"Eur J Immunol"},{"issue":"2","key":"3060_CR121","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/eji.200324198","volume":"34","author":"B Scheel","year":"2004","unstructured":"Scheel B, et al. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol. 2004;34(2):537\u201347.","journal-title":"Eur J Immunol"},{"issue":"10","key":"3060_CR122","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.4161\/hv.25181","volume":"9","author":"KJ Kallen","year":"2013","unstructured":"Kallen KJ, et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive(\u00ae) vaccines. Hum Vaccin Immunother. 2013;9(10):2263\u201376.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"3060_CR123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004746","volume":"10","author":"M Schnee","year":"2016","unstructured":"Schnee M, et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis. 2016;10(6): e0004746.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"3060_CR124","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","volume":"7","author":"A Papachristofilou","year":"2019","unstructured":"Papachristofilou A, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2019;7(1):38.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3060_CR125","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nm.3424","volume":"20","author":"P Liehl","year":"2014","unstructured":"Liehl P, et al. Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nat Med. 2014;20(1):47\u201353.","journal-title":"Nat Med"},{"issue":"3","key":"3060_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100109","volume":"13","author":"C Bergougnan","year":"2020","unstructured":"Bergougnan C, et al. Physical and immunological barrier of human primary nasal epithelial cells from non-allergic and allergic donors. World Allergy Organ J. 2020;13(3): 100109.","journal-title":"World Allergy Organ J"},{"issue":"2","key":"3060_CR127","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cmi.2012.61","volume":"10","author":"Z Hua","year":"2013","unstructured":"Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol. 2013;10(2):103\u20136.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"3060_CR128","doi-asserted-by":"publisher","first-page":"6824","DOI":"10.4049\/jimmunol.0803001","volume":"182","author":"A Ablasser","year":"2009","unstructured":"Ablasser A, et al. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol. 2009;182(11):6824\u201333.","journal-title":"J Immunol"},{"issue":"5","key":"3060_CR129","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/jir.2016.0095","volume":"37","author":"H Kato","year":"2017","unstructured":"Kato H, Oh SW, Fujita T. RIG-I-like receptors and type I interferonopathies. J Interferon Cytokine Res. 2017;37(5):207\u201313.","journal-title":"J Interferon Cytokine Res"},{"issue":"3","key":"3060_CR130","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2010.01.020","volume":"140","author":"J Rehwinkel","year":"2010","unstructured":"Rehwinkel J, et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell. 2010;140(3):397\u2013408.","journal-title":"Cell"},{"issue":"7522","key":"3060_CR131","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nature13590","volume":"514","author":"D Goubau","year":"2014","unstructured":"Goubau D, et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5\u2019-diphosphates. Nature. 2014;514(7522):372\u20135.","journal-title":"Nature"},{"issue":"11","key":"3060_CR132","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.imbio.2013.06.007","volume":"218","author":"M Schlee","year":"2013","unstructured":"Schlee M. Master sensors of pathogenic RNA - RIG-I like receptors. Immunobiology. 2013;218(11):1322\u201335.","journal-title":"Immunobiology"},{"issue":"5","key":"3060_CR133","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.celrep.2012.10.005","volume":"2","author":"Q Feng","year":"2012","unstructured":"Feng Q, et al. MDA5 detects the double-stranded RNA replicative form in picornavirus-infected cells. Cell Rep. 2012;2(5):1187\u201396.","journal-title":"Cell Rep"},{"issue":"3","key":"3060_CR134","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","volume":"26","author":"S Linares-Fern\u00e1ndez","year":"2020","unstructured":"Linares-Fern\u00e1ndez S, et al. Tailoring mRNA vaccine to balance innate\/adaptive immune response. Trends Mol Med. 2020;26(3):311\u201323.","journal-title":"Trends Mol Med"},{"issue":"2","key":"3060_CR135","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.virol.2011.11.025","volume":"425","author":"JA Pulit-Penaloza","year":"2012","unstructured":"Pulit-Penaloza JA, Scherbik SV, Brinton MA. Activation of Oas1a gene expression by type I IFN requires both STAT1 and STAT2 while only STAT2 is required for Oas1b activation. Virology. 2012;425(2):71\u201381.","journal-title":"Virology"},{"issue":"1","key":"3060_CR136","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang E, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1):94.","journal-title":"Signal Transduct Target Ther"},{"key":"3060_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9111211","author":"HM Abdelzaher","year":"2021","unstructured":"Abdelzaher HM, et al. RNA vaccines against infectious diseases: vital progress with room for improvement. Vaccines. 2021. https:\/\/doi.org\/10.3390\/vaccines9111211.","journal-title":"Vaccines"},{"issue":"20","key":"3060_CR138","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383(20):1920\u201331.","journal-title":"N Engl J Med"},{"issue":"20","key":"3060_CR139","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","volume":"39","author":"L Chu","year":"2021","unstructured":"Chu L, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021;39(20):2791\u20139.","journal-title":"Vaccine"},{"issue":"5","key":"3060_CR140","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med"},{"key":"3060_CR141","unstructured":"Sahin U, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. medRxiv, 2020: p. 2020.12.09.20245175."},{"issue":"27","key":"3060_CR142","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"3","key":"3060_CR143","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","volume":"22","author":"PG Kremsner","year":"2022","unstructured":"Kremsner PG, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial. Lancet Infect Dis. 2022;22(3):329\u201340.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"3060_CR144","volume":"2","author":"A Hekele","year":"2013","unstructured":"Hekele A, et al. Rapidly produced SAM(\u00ae) vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect. 2013;2(8): e52.","journal-title":"Emerg Microbes Infect"},{"issue":"25","key":"3060_CR145","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","volume":"37","author":"RA Feldman","year":"2019","unstructured":"Feldman RA, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326\u201334.","journal-title":"Vaccine"},{"issue":"10101","key":"3060_CR146","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","volume":"390","author":"M Alberer","year":"2017","unstructured":"Alberer M, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511\u201320.","journal-title":"Lancet"},{"issue":"8","key":"3060_CR147","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","volume":"39","author":"C Aldrich","year":"2021","unstructured":"Aldrich C, et al. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vaccine. 2021;39(8):1310\u20138.","journal-title":"Vaccine"},{"issue":"5","key":"3060_CR148","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0035-9203(52)90042-4","volume":"46","author":"GW Dick","year":"1952","unstructured":"Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46(5):509\u201320.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"3060_CR149","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cell.2016.09.020","volume":"167","author":"TC Pierson","year":"2016","unstructured":"Pierson TC, Graham BS. Zika virus: immunity and vaccine development. Cell. 2016;167(3):625\u201331.","journal-title":"Cell"},{"issue":"7644","key":"3060_CR150","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi N, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543(7644):248\u201351.","journal-title":"Nature"},{"issue":"5","key":"3060_CR151","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","volume":"23","author":"B Essink","year":"2023","unstructured":"Essink B, et al. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. Lancet Infect Dis. 2023;23(5):621\u201333.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"3060_CR152","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41541-023-00656-4","volume":"8","author":"B Bollman","year":"2023","unstructured":"Bollman B, et al. An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection. NPJ Vaccines. 2023;8(1):58.","journal-title":"NPJ Vaccines"},{"key":"3060_CR153","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.omtn.2019.03.003","volume":"15","author":"N Pardi","year":"2019","unstructured":"Pardi N, et al. Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques. Mol Ther Nucleic Acids. 2019;15:36\u201347.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"12","key":"3060_CR154","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1038\/s41591-021-01574-5","volume":"27","author":"P Zhang","year":"2021","unstructured":"Zhang P, et al. A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat Med. 2021;27(12):2234\u201345.","journal-title":"Nat Med"},{"key":"3060_CR155","doi-asserted-by":"publisher","DOI":"10.3390\/biom13071088","author":"Y Xu","year":"2023","unstructured":"Xu Y, et al. Short carbon nanotube-based delivery of mRNA for HIV-1 vaccines. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13071088.","journal-title":"Biomolecules"},{"issue":"6697","key":"3060_CR156","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk0582","volume":"384","author":"Z Xie","year":"2024","unstructured":"Xie Z, et al. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies. Science. 2024;384(6697): eadk0582.","journal-title":"Science"},{"issue":"17","key":"3060_CR157","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1097\/QAD.0000000000002026","volume":"32","author":"L Leal","year":"2018","unstructured":"Leal L, et al. Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. AIDS. 2018;32(17):2533\u201345.","journal-title":"AIDS"},{"issue":"1","key":"3060_CR158","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13063-019-3409-1","volume":"20","author":"W de Jong","year":"2019","unstructured":"de Jong W, et al. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials. 2019;20(1):361.","journal-title":"Trials"},{"issue":"1","key":"3060_CR159","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3934\/microbiol.2021007","volume":"7","author":"OA Adesanya","year":"2021","unstructured":"Adesanya OA, et al. Bacillus Calmette-guerin (BCG): the adroit vaccine. AIMS Microbiol. 2021;7(1):96\u2013113.","journal-title":"AIMS Microbiol"},{"issue":"9","key":"3060_CR160","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","volume":"271","author":"GA Colditz","year":"1994","unstructured":"Colditz GA. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994;271(9):698\u2013702.","journal-title":"JAMA"},{"issue":"8986","key":"3060_CR161","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","volume":"346","author":"PE Fine","year":"1995","unstructured":"Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995;346(8986):1339\u201345.","journal-title":"Lancet"},{"key":"3060_CR162","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148291","author":"AK Singh","year":"2021","unstructured":"Singh AK, Netea MG, Bishai WR. BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI148291.","journal-title":"J Clin Invest"},{"issue":"11","key":"3060_CR163","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1128\/IAI.72.11.6324-6329.2004","volume":"72","author":"T Xue","year":"2004","unstructured":"Xue T, et al. RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection. Infect Immun. 2004;72(11):6324\u20139.","journal-title":"Infect Immun"},{"key":"3060_CR164","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1472-6750-10-77","volume":"10","author":"JC Lorenzi","year":"2010","unstructured":"Lorenzi JC, et al. Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis. BMC Biotechnol. 2010;10:77.","journal-title":"BMC Biotechnol"},{"key":"3060_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11010130","author":"SE Larsen","year":"2023","unstructured":"Larsen SE, et al. An RNA-based vaccine platform for use against Mycobacterium tuberculosis. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11010130.","journal-title":"Vaccines"},{"issue":"1","key":"3060_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93266-w","volume":"11","author":"R Sharma","year":"2021","unstructured":"Sharma R, et al. An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins. Sci Rep. 2021;11(1): 13836.","journal-title":"Sci Rep"},{"issue":"1","key":"3060_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-08506-4","volume":"12","author":"H Al Tbeishat","year":"2022","unstructured":"Al Tbeishat H. Novel in silico mRNA vaccine design exploiting proteins of M. tuberculosis that modulates host immune responses by inducing epigenetic modifications. Sci Rep. 2022;12(1): 4645.","journal-title":"Sci Rep"},{"issue":"4","key":"3060_CR168","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s11030-022-10515-4","volume":"27","author":"S Shahrear","year":"2023","unstructured":"Shahrear S, Islam A. Modeling of MT. P495, an mRNA-based vaccine against the phosphate-binding protein PstS1 of Mycobacterium tuberculosis. Mol Divers. 2023;27(4):1613\u201332.","journal-title":"Mol Divers"},{"key":"3060_CR169","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11071264","author":"K Khalid","year":"2023","unstructured":"Khalid K, Poh CL. The promising potential of reverse vaccinology-based next-generation vaccine development over conventional vaccines against antibiotic-resistant bacteria. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11071264.","journal-title":"Vaccines"},{"issue":"2","key":"3060_CR170","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12539-021-00438-3","volume":"13","author":"G Selvaraj","year":"2021","unstructured":"Selvaraj G, et al. Are the allergic reactions of COVID-19 vaccines caused by mRNA constructs or nanocarriers? Immunological insights. Interdiscip Sci. 2021;13(2):344\u20137.","journal-title":"Interdiscip Sci"},{"issue":"2","key":"3060_CR171","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1067\/mai.2000.108434","volume":"106","author":"RC Aalberse","year":"2000","unstructured":"Aalberse RC. Structural biology of allergens. J Allergy Clin Immunol. 2000;106(2):228\u201338.","journal-title":"J Allergy Clin Immunol"},{"key":"3060_CR172","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.biomaterials.2016.09.006","volume":"109","author":"KJ Kauffman","year":"2016","unstructured":"Kauffman KJ, et al. Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo. Biomaterials. 2016;109:78\u201387.","journal-title":"Biomaterials"},{"issue":"1","key":"3060_CR173","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/mt.2009.208","volume":"18","author":"MT Abrams","year":"2010","unstructured":"Abrams MT, et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther. 2010;18(1):171\u201380.","journal-title":"Mol Ther"},{"key":"3060_CR174","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jconrel.2018.07.026","volume":"286","author":"S Chen","year":"2018","unstructured":"Chen S, et al. Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids. J Control Release. 2018;286:46\u201354.","journal-title":"J Control Release"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03060-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03060-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03060-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:41:38Z","timestamp":1757421698000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03060-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":174,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3060"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03060-x","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"792"}}